299 related articles for article (PubMed ID: 25262541)
1. Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines.
de Vicente J; Lemoine R; Bartlett M; Hermann JC; Hekmat-Nejad M; Henningsen R; Jin S; Kuglstatter A; Li H; Lovey AJ; Menke J; Niu L; Patel V; Petersen A; Setti L; Shao A; Tivitmahaisoon P; Vu MD; Soth M
Bioorg Med Chem Lett; 2014 Nov; 24(21):4969-75. PubMed ID: 25262541
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes.
Gehringer M; Pfaffenrot E; Bauer S; Laufer SA
ChemMedChem; 2014 Feb; 9(2):277-81. PubMed ID: 24403205
[TBL] [Abstract][Full Text] [Related]
3. Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802.
Norman P
Expert Opin Ther Pat; 2014 Jan; 24(1):121-5. PubMed ID: 24147573
[TBL] [Abstract][Full Text] [Related]
4. Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome.
Lynch SM; DeVicente J; Hermann JC; Jaime-Figueroa S; Jin S; Kuglstatter A; Li H; Lovey A; Menke J; Niu L; Patel V; Roy D; Soth M; Steiner S; Tivitmahaisoon P; Vu MD; Yee C
Bioorg Med Chem Lett; 2013 May; 23(9):2793-800. PubMed ID: 23540648
[TBL] [Abstract][Full Text] [Related]
5. Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres.
Gehringer M; Forster M; Pfaffenrot E; Bauer SM; Laufer SA
ChemMedChem; 2014 Nov; 9(11):2516-27. PubMed ID: 25139757
[TBL] [Abstract][Full Text] [Related]
6. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors.
Jaime-Figueroa S; De Vicente J; Hermann J; Jahangir A; Jin S; Kuglstatter A; Lynch SM; Menke J; Niu L; Patel V; Shao A; Soth M; Vu MD; Yee C
Bioorg Med Chem Lett; 2013 May; 23(9):2522-6. PubMed ID: 23541670
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).
Ostrovskyi D; Rumpf T; Eib J; Lumbroso A; Slynko I; Klaeger S; Heinzlmeir S; Forster M; Gehringer M; Pfaffenrot E; Bauer SM; Schmidtkunz K; Wenzler S; Metzger E; Kuster B; Laufer S; Schüle R; Sippl W; Breit B; Jung M
Future Med Chem; 2016 Sep; 8(13):1537-51. PubMed ID: 27572962
[TBL] [Abstract][Full Text] [Related]
9. Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors.
Wang Y; Huang W; Xin M; Chen P; Gui L; Zhao X; Tang F; Wang J; Liu F
Bioorg Med Chem; 2017 Jan; 25(1):75-83. PubMed ID: 27771180
[TBL] [Abstract][Full Text] [Related]
10. Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.
Duan JJ; Lu Z; Jiang B; Yang BV; Doweyko LM; Nirschl DS; Haque LE; Lin S; Brown G; Hynes J; Tokarski JS; Sack JS; Khan J; Lippy JS; Zhang RF; Pitt S; Shen G; Pitts WJ; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; McKinnon M; Fura A; Schieven GL; Wrobleski ST
Bioorg Med Chem Lett; 2014 Dec; 24(24):5721-5726. PubMed ID: 25453808
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ
J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636
[TBL] [Abstract][Full Text] [Related]
12. Novel Mps1 kinase inhibitors: from purine to pyrrolopyrimidine and quinazoline leads.
Bursavich MG; Dastrup D; Shenderovich M; Yager KM; Cimbora DM; Williams B; Kumar DV
Bioorg Med Chem Lett; 2013 Dec; 23(24):6829-33. PubMed ID: 24183538
[TBL] [Abstract][Full Text] [Related]
13. Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.
Thorarensen A; Dowty ME; Banker ME; Juba B; Jussif J; Lin T; Vincent F; Czerwinski RM; Casimiro-Garcia A; Unwalla R; Trujillo JI; Liang S; Balbo P; Che Y; Gilbert AM; Brown MF; Hayward M; Montgomery J; Leung L; Yang X; Soucy S; Hegen M; Coe J; Langille J; Vajdos F; Chrencik J; Telliez JB
J Med Chem; 2017 Mar; 60(5):1971-1993. PubMed ID: 28139931
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibitors of the Janus kinase Jak3--Are they effective?
Thoma G; Drückes P; Zerwes HG
Bioorg Med Chem Lett; 2014 Oct; 24(19):4617-4621. PubMed ID: 25217444
[TBL] [Abstract][Full Text] [Related]
15. A receptor-independent, cell-based JAK activation assay for screening for JAK3-specific inhibitors.
Oh K; Joo KM; Jung YS; Lee J; Kang H; Lee HY; Lee DS
J Immunol Methods; 2010 Mar; 354(1-2):45-52. PubMed ID: 20138049
[TBL] [Abstract][Full Text] [Related]
16. [Research progress of JAK-3 kinase and its inhibitors].
Yin Y; Zhang TT; Zhang DY
Yao Xue Xue Bao; 2016 Oct; 51(10):1520-9. PubMed ID: 29932316
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro.
Wang SP; Iwata S; Nakayamada S; Sakata K; Yamaoka K; Tanaka Y
Ann Rheum Dis; 2014 Dec; 73(12):2213-5. PubMed ID: 25157177
[No Abstract] [Full Text] [Related]
19. Insights into kinetic mechanism of Janus kinase 3 and its inhibition by tofacitinib.
Hekmatnejad M; Conwell S; Lok SM; Kutach A; Shaw D; Fang E; Swinney DC
Arch Biochem Biophys; 2016 Dec; 612():22-34. PubMed ID: 27555492
[TBL] [Abstract][Full Text] [Related]
20. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.
Thoma G; Nuninger F; Falchetto R; Hermes E; Tavares GA; Vangrevelinghe E; Zerwes HG
J Med Chem; 2011 Jan; 54(1):284-8. PubMed ID: 21155605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]